

IN THE SPECIFICATION:

Please replace the title at page 1, lines 3-4 with the following amended title:

~~Novel Genes Encoding Proteins Having Diagnostic, Preventive, Therapeutic, and Other Uses~~
Method of Identifying Inhibitors of the Human Lipase TANGO 294

Please replace the abstract at page 171 with the following amended abstract:

ABSTRACT OF THE DISCLOSURE

~~The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.~~
The present invention provides methods for identifying compounds capable of binding to human lipase TANGO 294 polypeptides. The present invention also provides methods for identifying compounds capable of modulating the activity of human lipase TANGO 294 polypeptides.

At page 71, beginning at line 2, please amend the paragraph as follows:

~~TaqMan™~~ TAQMAN® Real Time Polymerase Chain Reaction (PCR) Experiments

At page 71, beginning at line 14, please amend the paragraph as follows:

Novel TANGO 294 expression was measured by ~~TaqMan®~~ TAQMAN® quantitative PCR (Perkin Elmer Applied Biosystems) in cDNA prepared from the following human tissues:

At pages 73 and 74, beginning at line 20 of page 73, please amend the paragraph as follows:

Probes were designed by PrimerExpress software (PE Biosystems) based on the sequence of each gene. Each gene probe was labeled using FAM (6-carboxyfluorescein), and the beta-2 microglobulin reference probe was labeled with a different fluorescent dye, VIC. The differential labeling of the target gene and internal reference gene thus enabled measurement in same well. Forward and reverse primers and the probes for both beta-2 microglobulin and target gene were added to the ~~TaqMan®~~ TAQMAN® Universal PCR Master Mix (PE Applied Biosystems). Although the final concentration of primer and probe could vary, each was internally consistent within a given experiment. A typical experiment contained 200 nanomolar of forward and reverse primers plus 100 nanomolar probe for beta-2 microglobulin and 600 nanomolar forward and reverse primers plus 200 nanomolar probe for the target gene. ~~TaqMan~~ TAQMAN® matrix experiments were carried out on an ABI PRISM 7700 Sequence Detection System (PE Applied Biosystems). The thermal cycler conditions were as follows: hold for 2 minutes at 50°C and 10 minutes at 95°C, followed by two-step PCR for 40 cycles of 95°C for 15 seconds followed by 60°C for 1 minute.

At pages 74 and 75, beginning at line 16 of page 74, please amend the paragraphs as follows:

The ~~TaqMan~~ TAQMAN® expression from Panel One shows restricted TANGO 294 expression in pancreas, colon tumors, and activated peripheral blood mononuclear cells, with highest expression in colon tumors.

The ~~TaqMan~~ TAQMAN® expression from Panel Two shows TANGO 294 expression restricted to colon tumors and lung tumors, with a 4-50 times increase in expression in colon tumor samples over normal colon samples. For example, the colon tumor sample NDR 210 shows about 6× expression over normal colon samples, the colon tumor sample CHT 382 shows

about 9× expression over normal colon samples, and the colon tumor sample CHT 528 shows about 30× expression over normal colon samples.

The ~~FaqMan~~ TAQMAN® expression from Panel Three shows TANGO 294 elevated expression in adenomas and stage A, B, and C, and metastatic tumors.

The ~~FaqMan~~ TAQMAN® expression from Panel Four shows TANGO 294 expression in breast, colon, and lung cell lines (NCIH322 and NHBE).

The ~~FaqMan~~ TAQMAN® expression from Panel Five shows upregulated TANGO 294 expression in 80% of colon to liver metastases. Both normal colon and normal liver show no expression.